ARS Pharmaceuticals announced pre-ordering services for neffy, ensuring swift access upon availability, expected in late September. Recently, the U.S. Food and Drug Administration, FDA, approved neffy for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals announces EC approval for EURneffy
- Medtronic, Palo Alto Networks report quarterly beats: Morning Buzz
- Vornado upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
- Cantor starts ARS at Overweight, sees 111% potential upside